Related Experiment Video

Updated: Jun 30, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

[The effect of losartan on glomerular sclerosis in rats with diabetic nephropathy]

Jun-ying Xu1, Li-jian Tao, Ling Wang

  • 1Department of Nephrology, Xiangya Hospital, Central South University, Changsha 410008,China.

Zhong Nan Da Xue Xue Bao. Yi Xue Ban = Journal of Central South University. Medical Sciences
|September 25, 2008
PubMed
Abstract

Insights

Losartan treatment reduced glomerular sclerosis and collagen Type IV accumulation in rats with diabetic nephropathy by inhibiting transforming growth factor-beta1 (TGF-β1) and connective tissue growth factor (CTGF).

Area of Science:

  • Nephrology
  • Pharmacology
  • Biochemistry

Context:

  • Diabetic nephropathy is a major complication of diabetes, characterized by extracellular matrix accumulation and glomerular sclerosis.
  • Losartan, an angiotensin II receptor blocker, is used to treat hypertension and diabetic nephropathy.
  • The precise mechanisms by which losartan affects extracellular matrix metabolism in diabetic nephropathy require further elucidation.

Purpose:

  • To investigate the effects of losartan on extracellular matrix degradation in a rat model of diabetic nephropathy.
  • To explore the molecular mechanisms underlying losartan's renoprotective effects, focusing on key fibrotic factors.

Summary:

  • Diabetic nephropathy was induced in rats using streptozotocin (STZ).
  • Rats were treated with losartan for 16 weeks, and renal function markers (serum creatinine, blood urea nitrogen) and glomerular sclerosis index (GSI) were assessed.
  • Expression levels of collagen Type IV, connective tissue growth factor (CTGF), and transforming growth factor-beta1 (TGF-β1) were quantified using Western blot and real-time PCR.
  • Losartan treatment significantly reduced blood urea nitrogen, GSI, and the expression of collagen Type IV, CTGF, and TGF-β1 at both protein and mRNA levels compared to the model group.

Impact:

  • This study reveals that losartan mitigates glomerular sclerosis and extracellular matrix deposition in diabetic nephropathy.
  • The findings highlight the inhibitory role of losartan on TGF-β1 and CTGF pathways, crucial mediators of fibrosis.
  • Understanding these mechanisms provides a basis for optimizing therapeutic strategies targeting diabetic kidney disease progression.

More Related Videos

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...